Clinical Trial Details
EORTC-06061
Back to Clinical Trials Database
Clofarabine in combination with a standard remissioninduction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) : a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial)
| Trial Status | All trial activities ended |
|---|---|
| Dates |
Date of activation: 21-Nov-2008 Date Step1 close: 16-May-2013 |
| Data management at EORTC | Yes |
| Design |
Phase 1-2 Randomized open label |
| Targeted Sample size | EORTC Groups: 77 - All Groups: 90 |
| Treatment | |
| Study Staff | |
| Type of cancer | |
| Participating groups | |
| Protocol summary | http://clinicaltrials.gov/study/NCT00838240 |
| NCT number | NCT00838240 |
| EudraCT | 2006-004912-28 |
